MBIO - Mustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancers

Mustang Bio (MBIO) announces updated interim data from Phase 1/2 clinical trial investigating the safety and efficacy of MB-106 CD20-targeted, autologous CAR T cell therapy for high-risk B-cell non-Hodgkin lymphomas (B-NHL) and chronic lymphocytic leukemia ((CLL)).MBIO shares rise 7% premarket trading at $4.08.In the 15 patients treated, the overall response rate ((ORR)) was 93% (14/15) with a complete response ((CR)) rate of 67% (10/15).In 11 patients with follicular lymphoma ((FL)), ORR and CR were 91% (10/11) and 82% (9/11), respectively.CAR T persistence was seen in all dose levels ((DL)) and, while expansion was faster in higher DL, the levels were comparable by day 28."We are pleased that all complete responders continue to remain in remission, and we continue to enroll all eligible CD20+ NHL and CLL patients into this trial,” commented Mazyar Shadman, M.D., M.P.H., Associate Professor, Clinical Research Division of Fred Hutch.The data were presented at the EHA 2021.#EHA21

For further details see:

Mustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancers